Pharmacokinetics and metabolism of sirolimus

Therapeutic Drug Monitoring

Volumn 22, Issue 1, 2000, Pages 31-35

  Gallant Haidner, Heather L ^a   Trepanier, Daniel J ^b   Freitag, Derrick G ^b   Yatscoff, Randall W ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Isotechnika Inc   (Canada)

Author keywords

Metabolism; Pharmacokinetics; Sirolimus (rapamycin, Rapamune); Therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN A; PREDNISONE; RAPAMYCIN;

AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOTRANSFORMATION; CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS;

EID: 0033953374     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200002000-00006     Document Type: Article

References (29)

1. Seghal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic: II. Fermentation, isolation and characterization. J Antibiot 1975;28:727-32.
2. Morris RE. Rapamycins: antifungal, antitumor, antiproliferatives and immunosuppressive macrolides. Transplant Rev 1992;6:39-87.
3. Kahan BD, Chang JY, Sehgal SN. Preclinical evaluation of a potent immunosuppressive agent, rapamycin. Transplantation 1991;52:185-91.
4. Fryer J, Yatscoff RW, Pascoe EA, Thliveris J. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model. Transplantation 1993;55:340-5.
5. Collier DJS, Calne RY, Thiru S, et al. Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc 1990;22:1674-5.
6. Almond P, Moss A, Nakhleh R et al. Rapamycin in a porcine renal transplant model. Ann N Y Aca Sci 1993;685:121-2.
7. Stepkowkski SM, Chen H, Daloze P, Kahan BD. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney and small bowel transplantation in the rat. Transplantation 1991;51:22-32.
8. Kimball PM, Kerman RH, Kahan BD. Production of synergistic, nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine A. Transplantation 1991;51:486-90.
9. Metcalfe SM, Richards FM. Cyclosporine, FK506 and rapamycin: some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. Transplantation 1990;49:798-800.
10. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou TC. Synergistic interactions of cyclosporine A and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991;51:232-9.
11. Tu Y, Stepkowski SM, Chou TC et al. The synergistic effects of cyclosporine, sirolimus and brequinar on heart allograft survival in mice. Transplantation 1995;59:177-83.
12. Knight R, Ferraresso M, Serino F et al. Low-dose rapamycin potentiates the effect of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993;55:947-9.
13. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressant drugs: a review. J Am Soc Nephrol 1999;10:1366-80.
14. Yatscoff RW, Wang P, Chan K, Hicks D, Zimmerman J. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations. Ther Drug Monit 1995;17:666-71.
15. Ferron GM, Jusko WJ. Species differences in sirolimus stability in humans, rabbits and rats. Drug Met Dispos 1998;26:83-4.
16. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 1998;285:1104-12.
17. Kaplan B, Meier-Kriesche H, Napoli KL, Kahan BD. The effects of relative timing of sirolimis and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998;63:48-53.
18. Ferron GM, Jusko WJ. Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits. Pharm Res 1998;1888-1894.
19. Kaplan B, Meier-Kriesche H, Napoli KL, Kahan BD. Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant patients. Ther Drug Monit 1999;21:44-9.
20. Yacyshyn BR, Bowen-Yacyshyn MB, Pilarski LM. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Scan J Immunol 1996;43:449-55.
21. Crowe A, Bruelisauer A, Duerr L, Guntz P, Lemaire M. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999;27:627-32.
22. Sattler M, Guengerich FP, Yun C-H, Christians U, Sewing K-F. Cytochrome P-450 enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Met Dispos 1992;20:753-61.
23. Christians U, Sattler M, Schiebel HM et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Met Dispos 1992;20:186-91.
24. Streit F, Christians U, Schiebel H-M, Meyer A, Sewing K-F. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes. Drug Met Dispos 1996;24:1272-8.
25. Wang PC, Lim HK, Chan KW, Scatina J, Sisenwisne SF. Isolation of ten metabolites from the bile of rats receiving rapamycin (sirolimus) intravenously. ISSX Proc 1995;8:136.
26. Wang PC, Chan KW, Schiksnis RA, Scatina J, Sisenwisne SF. High performance liquid Chromatographic isolation, spectroscopic characterization, and immunosuppressive activities of two rapamycin degradation products. J Liquid Chrom B 1994;17:3383-92.
27. Chan K, Wang P, Scantina J et al. Characterization of biliary rapamycin metabolites by ionspray liquid chromatography/mass spectrometry [abstract]. In: Proceedings of the 41st ASMS Conference on Mass Spectrometry and Allied Topics; 1993; San Francisco, CA; p545 edition.
28. Kuhnt M, Bitsch F, Ponelle M, Fehr T, Sanglier J-J. Microbial conversion of rapamycin. Enz Microb Tech 1997;21:405-12.
29. Streit F, Christians U, Sheilbel H-M et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem 1996;42:1417-25.